An Evaluation of Product Usage for Molecular Testing with 11 European Countries

Evaluierung von verwendeten NAT technologien und Produkten für die Diagnose von Infectionskrankheiten, 42 Erreger / alle Angaben pro Erreger (Chlamydia trachomatis, Neisseria gonorrhoeae, HIV, HCV, Mycobacterium tuberculosis, Mycobacterium avium, Legionella pneumophilia, Chlamydia sp., Mycoplasma pneumoniae, CMV, quantitative/qualitative, HSV 1,2, Enterovirus, West Nile Virus, SARS, Adenovirus, Influenza A, Influenza A and B, RSV, Parainfluenza, HPV, Chronic Meningitis, Blastomyces, Histoplasma, Cryptococcus, Coccidioides, TB, Neisseria meningitidis, Haemophilus, Pneumokokken, Listeria, Enterobacteriacea, RMSF, Babesia, Ehrlichia, Anaplasma, Borrelia, MRSA, Fungi) und Land (G, UK, F, It, Es, Ch, Be, No, Se, Dk, Fi)

Key Reasons to buy this report:
• Assess current market realities in terms of currently performed tests / Used technologies at an unparalleled level of segmentation
• Get detailed knowledge on suppliers of molecular test kits / equipment, (by segmentation criteria)
• Reflect the current situation not only at a specific point in time, but monitor trends over a period of time (both in terms of market participants as well as system types)
• Model market and own sales forecasts on system types based on investment plans of
customers
• Reflect the expected behaviour of buyers, not just the expectations of sellers but by the motivations of buyers.
• Model market forecasts on associated product lines (e.g. PCR Cycler, NAT related devices) based on procedure data
• Make decisions regarding the market entry/marketing strategy
[Fade out the market survey infos]

Pro Land:
1.1 Project Objectives 5
1.2 Definitions 7
1.3 German Health Care System and Reimbursement

Healthcare System

Reimbursement Policies

Private Laboratories - EBM

Hospital Laboratories

Maternity Services

IGeL - Individual Health Services

1.4 German Laboratory Landscape

1.5 Respondent Population Germany

2. Infectious Diseases Testing in Clinical Laboratories

2.1 Sexual Transmitted Diseases (STD)

Chlamydia Trachomatis

Neisseria

HIV

HCV

Group B Streptococcus

HSV

2.2 Mycobacteria

Mycobacteria Tuberculosis

Mycobacteria Avium

Mycobacteria – NA Purification

2.3 Atypical Pneumoniae

Bordetella

Legionella

Chlamydia sp.

Mycoplasma Pneumoniae

2.4 Cytomegalovirus (CMV)

CMV – Qualitative Tests

CMV – Quantitative Tests

2.5. Viral Meningitis

HSV 1 & 2

Enterovirus

West Nile Virus (WNV)

Epstein Barr Virus (EBV)

VZV

2.6 Respiratory Viruses

SARS

Adenovirus

Influenza A

Influenza A&B

RSV

Parainfluenza

2.7 HPV

2.8 Chronic Meningitis

2.9 Bacterial Meningitis

Neisseria Meningitis

Haemophilus Influenza

Pneumococcae

Listeria

Enterobacteria

2.10 Tick Born Encephalitis

2.11 Antibiotic Resistant Bacteria

MRSA

VRE

2.12 Candida

3. Equipment & Purchase

3.1 Current Installations & Financing of Laboratory Equipment

Cobas Amplicor, Roche

Light Cycler, Roche

ABI PRISM, Applied Biosystems

RotorGene, Corbett Research

Other Cycler

Other Devices/Manufacturers

3.2 Budget Resources

3.3 Who is Involved in Purchasing Decisions

3.4 How do Laboratories Purchase
3.5 Criteria Influence a Purchasing

Decision

3.6 What are Laboratories Willing to Pay for New Tests?

4. Market Sizes and Market Shares

4.1 Market Volumes for Selected Pathogens

STD

Mycobacteria Tuberculosis

Atypical Pneumonia

CMV

Viral Meningitis

Respiratory Viruses

HPV

MRSA

4.2 Market Shares

5. Market Trends

5.1 Problems with Molecular Diagnostics

5.2 Expected Growth per Segment

5.3 Other Growth Areas

5.4 Drivers for Molecular Diagnostics

5.5 Restraints for Molecular Diagnostics

6. Political Influences

6.1 Changes of Reimbursement Policy

6.2 Influence of the EU IVD Act

[Fade out table of contents]